^
Association details:
| Biomarker: | MYC rearrangement + BCL2 rearrangement |
|---|---|
| Cancer: | Follicular Lymphoma |
| Regimen: | (vincristine + Rituxan (rituximab) + doxorubicin hydrochloride + prednisone + cyclophosphamide + etoposide IV) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FOLLICULAR LYMPHOMA WITH C-MYC REARRANGEMENT. PLACE OF THERAPY INTENSIFICATION.
Published date:
05/17/2018
Excerpt:
In a group of 5 pts after R-DA-EPOCH, 2 pts had complete remission (CR) (one case of FL 3A with c-MYC/BCL2-R, another case of FL 3B with solely c-MYC-R), 3 pts needed second-line treatment (R-DHAP) due to progressive disease (PD) (2 cases of FL 3B with c-MYC/BCL6-R) or partial remission (PR) (1 case of FL 3A with c-MYC/BCL2-R). The last one achieved CR after 2 R-DHAP, later auto-SCT was performed. Another pt had stable disease (SD), auto-SCT was planned.
